For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Tafamidis meglumine represents a genuine change. These novel therapies preserve the transthyretin protein, halting its harmful build-up and lessening the impact of the condition . Patients are now experiencing benefit… Read More